Gilead Sciences Inc
GILD
Company Profile
Business description
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
Contact
333 Lakeside Drive
Foster CityCA94404
USAT: +1 650 574-3000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
17,000
Gilead Sciences Inc News & Analysis
stocks
10 cheap wide-moat US stocks for 2025
Undervalued high-quality names from the Morningstar Wide Moat Focus Index are attractive stocks to buy for long-term investors.
personal-finance
US stock market outlook: tariffs are 2025's wild card
Macrodynamic tailwinds persist, but stocks are already priced to perfection. Will tariffs derail the market in 2025?
stocks
10 cheap US dividend-growth stocks to buy
The stocks of these companies with a history of dividend increases look undervalued today.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,122.70 | 62.80 | -0.68% |
| CAC 40 | 8,485.64 | 77.37 | 0.92% |
| DAX 40 | 25,612.03 | 151.55 | 0.60% |
| Dow JONES (US) | 52,208.06 | 613.92 | 1.19% |
| FTSE 100 | 10,897.27 | 11.14 | -0.10% |
| HKSE | 25,858.88 | 50.96 | 0.20% |
| NASDAQ | 25,122.18 | 679.24 | 2.78% |
| Nikkei 225 | 61,867.43 | 433.24 | 0.71% |
| NZX 50 Index | 13,762.78 | 213.89 | -1.53% |
| S&P 500 | 7,437.63 | 121.48 | 1.66% |
| S&P/ASX 200 | 8,967.70 | 57.10 | -0.63% |
| SSE Composite Index | 3,804.69 | 23.78 | -0.62% |